WO2023122325A3 - Meta anilide compounds and methods for use of the same to treat diseases and disorders - Google Patents
Meta anilide compounds and methods for use of the same to treat diseases and disorders Download PDFInfo
- Publication number
- WO2023122325A3 WO2023122325A3 PCT/US2022/053923 US2022053923W WO2023122325A3 WO 2023122325 A3 WO2023122325 A3 WO 2023122325A3 US 2022053923 W US2022053923 W US 2022053923W WO 2023122325 A3 WO2023122325 A3 WO 2023122325A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- meta
- methods
- disorders
- same
- treat diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Disclosed herein are meta anilide inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, and methods for their use in treating or preventing diseases, such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are as described.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163293335P | 2021-12-23 | 2021-12-23 | |
US63/293,335 | 2021-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023122325A2 WO2023122325A2 (en) | 2023-06-29 |
WO2023122325A3 true WO2023122325A3 (en) | 2023-08-03 |
Family
ID=86903654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/053923 WO2023122325A2 (en) | 2021-12-23 | 2022-12-23 | Meta anilide compounds and methods for use of the same to treat diseases and disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023122325A2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016073847A2 (en) * | 2014-11-07 | 2016-05-12 | The Regents Of The University Of Michigan | Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same |
WO2019055590A1 (en) * | 2017-09-13 | 2019-03-21 | Amgen Inc. | Bisamide sarcomere activating compounds and uses thereof |
WO2019089729A1 (en) * | 2017-10-31 | 2019-05-09 | University Of Miami | Kinase inhibitors for the treatment of central and peripheral nervous system disorders |
WO2021071806A1 (en) * | 2019-10-07 | 2021-04-15 | D. E. Shaw Research, Llc | Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers |
-
2022
- 2022-12-23 WO PCT/US2022/053923 patent/WO2023122325A2/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016073847A2 (en) * | 2014-11-07 | 2016-05-12 | The Regents Of The University Of Michigan | Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same |
US10662183B2 (en) * | 2014-11-07 | 2020-05-26 | The Regents Of The University Of Michigan | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same |
WO2019055590A1 (en) * | 2017-09-13 | 2019-03-21 | Amgen Inc. | Bisamide sarcomere activating compounds and uses thereof |
WO2019089729A1 (en) * | 2017-10-31 | 2019-05-09 | University Of Miami | Kinase inhibitors for the treatment of central and peripheral nervous system disorders |
WO2021071806A1 (en) * | 2019-10-07 | 2021-04-15 | D. E. Shaw Research, Llc | Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers |
Non-Patent Citations (1)
Title |
---|
DATABASE PUBCHEM COMPOUND ANONYMOUS : "N-(4-Chlorophenyl)-5,5-difluoro-1-[3-(2-pyridinyl)benzoyl]-3-piperidinecarboxamide", XP093083313, retrieved from PUBCHEM * |
Also Published As
Publication number | Publication date |
---|---|
WO2023122325A2 (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202191177A1 (en) | 2-AMINO-N-HETEROARYLNICOTINAMIDES AS NAV1.8 INHIBITORS | |
CR20220584A (en) | Fused tricyclic kras inhibitors | |
MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
MX2020013570A (en) | Purinone compounds and their use in treating cancer. | |
MX2023007192A (en) | Prmts inhibitors. | |
MX2022015581A (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors. | |
WO2008074997A8 (en) | Pyridine benzamides and pyrazine benzamides used as pkd inhibitors | |
MX2019000536A (en) | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme. | |
MX2022015531A (en) | Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof. | |
MX2023009222A (en) | Tricyclic-amido-bicyclic prmt5 inhibitors. | |
MX2018013325A (en) | Adenine derivatives as protein kinase inhibitors. | |
CR20230519A (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
MX2023008968A (en) | Cdk2 inhibitors and methods of using the same. | |
CR20240059A (en) | Tricyclic compounds as inhibitors of kras | |
WO2019195641A3 (en) | 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same | |
WO2023122325A3 (en) | Meta anilide compounds and methods for use of the same to treat diseases and disorders | |
JOP20220186A1 (en) | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | |
MX2023007150A (en) | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof. | |
AU2018276273A1 (en) | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | |
MX2023011057A (en) | Indoline derivatives as ddr1 and ddr2 inhibitors. | |
MX2023001618A (en) | Heterocyclic compound as bcl-2 inhibitor. | |
MX2023007218A (en) | Cocrystal of a cdk inhibitor. | |
MX2022001158A (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy. | |
MX2021012499A (en) | Improved inhibitors of the notch transcriptional activation complex and methods for use of the same. | |
WO2018067638A3 (en) | High mobility group b1 protein inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22912519 Country of ref document: EP Kind code of ref document: A2 |